EGFR and non-small cell lung carcinoma: As a novel third-generation EGFR-TKI, furmonertinib (alflutinib/AST2818) has been approved by the National Medical Products Administration (NMPA) of China for pretreated patients with NSCLC harboring an EGFR T790M mutation.